Both in Biotechnology
Novavax vs Recursion Pharmaceuticals
Over the past year NVAX returned +13.8% and RXRX returned −38.7%; their daily moves had a correlation of 0.47.
NVAX +13.8% RXRX −38.7%Growth of $1, one year, split-adjusted
| Metric | NVAX | RXRX |
|---|---|---|
| Price | $9.70 | $3.70 |
| Market cap | $1.60B | $1.98B |
| Today | −2.90% | +3.35% |
| 1 month | −8.5% | −4.9% |
| 6 months | +18.0% | +5.4% |
| Year to date | +44.3% | −9.5% |
| 1 year | +14.7% | −35.7% |
| Revenue growth (YoY) | −76.3% | −60.1% |
| Gross margin | 74.9% | −49.8% |
| Net margin | −94.2% | −1708.0% |
| P/E (TTM) | — | — |
| Price / sales | 3.9× | 36.2× |
| Net cash | $422.0M | $531.5M |
| Dividend yield | — | — |
| Volatility (60d) | 78.2% | 93.2% |
| Short % of float | 29.5% | 36.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).